Document Detail


Valproate-induced hyperammonemic encephalopathy.
MedLine Citation:
PMID:  16774619     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Valproate-induced hyperammonemic encephalopathy (VHE) is an unusual complication characterized by a decreasing level of consciousness, focal neurological deficits, cognitive slowing, vomiting, drowsiness, and lethargy. We have thoroughly reviewed the predisposing factors and their screening, the biochemical and physiopathological mechanisms involved, the different treatments described, and those that are being investigated. Etiopathogenesis is not completely understood, although hyperammonemia has been postulated as the main cause of the clinical syndrome. The increase in serum ammonium level is due to several mechanisms, the most important one appearing to be the inhibition of carbamoylphosphate synthetase-I, the enzyme that begins the urea cycle. Polytherapy with several drugs, such as phenobarbital and topiramate, seems to contribute to hyperammonemia. Hyperammonemia leads to an increase in the glutamine level in the brain, which produces astrocyte swelling and cerebral edema. There are several studies that suggest that treatment with supplements of carnitine can lead to an early favorable clinical response due to the probable carnitine deficiency induced by a valproate (VPA) treatment. Development of the progressive confusional syndrome, associated with an increase in seizure frequency after VPA treatment onset, obliges us to rule out VHE by screening for blood ammonium levels and the existence of urea cycle enzyme deficiency, such as ornithine carbamoyltransferase deficiency. Electroencephalography (EEG) is characterized by signs of severe encephalopathy with continuous generalized slowing, a predominance of theta and delta activity, occasional bursts of frontal intermittent rhythmic delta activity, and triphasic waves. These EEG findings, as well as clinical manifestations and hyperammonemia, tend to normalize after VPA withdrawal.
Authors:
N Segura-Bruna; A Rodriguez-Campello; V Puente; J Roquer
Related Documents :
23386729 - Treatment quality indicators predict short-term outcomes in patients with diabetes: a p...
24118149 - Diabetic major amputation in far north queensland 1998-2008: what is the gap for indige...
23086589 - Outcomes from a diabetes self-management intervention for native hawaiians and pacific ...
6338859 - Glucose intolerance in spinal cord injury.
24711709 - Tubulointerstitial disease in diabetic nephropathy.
23462149 - Prevention of the metabolic syndrome in igt subjects in a lifestyle intervention: resul...
124899 - Studies on the energy metabolism during anaerobic fermentation of glucose by baker's ye...
10376199 - Coronary risk factors influence plaque morphology in patients with unstable angina.
9231659 - Skeletal muscle myosin heavy chain synthesis in type 1 diabetes.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Acta neurologica Scandinavica     Volume:  114     ISSN:  0001-6314     ISO Abbreviation:  Acta Neurol. Scand.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-15     Completed Date:  2006-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370336     Medline TA:  Acta Neurol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  1-7     Citation Subset:  IM    
Affiliation:
Servei de Neurologia, Hospital del Mar, Barcelona, Spain. 94407@imas.imim.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticonvulsants / adverse effects*
Brain / metabolism,  physiopathology
Brain Edema / chemically induced,  metabolism,  physiopathology
Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) / antagonists & inhibitors,  metabolism
Carnitine / therapeutic use
Diagnosis, Differential
Glutamic Acid / metabolism*
Glutamine / metabolism
Hepatic Encephalopathy / chemically induced*,  diagnosis,  physiopathology
Humans
Hyperammonemia / chemically induced*,  metabolism,  physiopathology
Valproic Acid / adverse effects*
Chemical
Reg. No./Substance:
0/Anticonvulsants; 541-15-1/Carnitine; 56-85-9/Glutamine; 56-86-0/Glutamic Acid; 99-66-1/Valproic Acid; EC 6.3.5.5/Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Closing the loop: combining insulin pumps and glucose sensors in children with type 1 diabetes melli...
Next Document:  The epidemiology of post-stroke epilepsy according to stroke subtypes.